A Phase 3, Randomized, Double-blind, Parallel Trial to Confirm the Clinical Efficacy and Safety of Dasiglucagon in Rescue Treatment of Hypoglycemia in Subjects With Type 1 Diabetes Mellitus Compared to Placebo and With Reference to GlucaGen

Trial Profile

A Phase 3, Randomized, Double-blind, Parallel Trial to Confirm the Clinical Efficacy and Safety of Dasiglucagon in Rescue Treatment of Hypoglycemia in Subjects With Type 1 Diabetes Mellitus Compared to Placebo and With Reference to GlucaGen

Completed
Phase of Trial: Phase III

Latest Information Update: 27 Jun 2018

At a glance

  • Drugs Dasiglucagon (Primary) ; Glucagon; Insulin glulisine
  • Indications Hypoglycaemia
  • Focus Registrational; Therapeutic Use
  • Sponsors Zealand Pharma
  • Most Recent Events

    • 01 Jun 2018 Status changed from active, no longer recruiting to completed.
    • 28 May 2018 According to a Zealand Pharma media release, all patients have been enrolled and dosed in this trial and results are expected in Q3 2018.
    • 02 May 2018 Planned End Date changed from 31 Aug 2018 to 15 Jun 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top